buyWeak cluster of 2
David R Ebsworth bought $189k of VRNA
director at Verona Pharma plc. 39,360 shares at an average of $4.80, traded Nov 6, 2024, filed Nov 7, 2024.
Conviction score
35Value
$189k
39,360 shares
Holdings after
920,003
+4% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleDirector
- +12Trade size$189k at market
- 0Relative to holdingsHoldings up 4.5%
- 0Price contextNo price history yet
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001104659-24-115418, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 6, 2024 | POpen-market purchase Ordinary Shares | +39,360 | $4.80 | $189k | 920,003 | Nov 7, 2024 |
Related signals
Other insiders at Verona Pharma plc and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | Verona Pharma plc | Christina Ackermann director | $24k 1,808 shares | -3% | |
| 36Weak | Verona Pharma plc | Michael Austwick director | $148k 11,288 shares | -47% | |
| 15Weak | Verona Pharma plc | James Aloysius Brady director | $11k 824 shares | -3% | |
| 31Weak | Verona Pharma plc | Kenneth Cunningham director | $142k 10,808 shares | -12% | |
| 30Weak | Verona Pharma plc | Lisa Deschamps director | $124k 9,464 shares | -10% | |
| 20Weak | Verona Pharma plc | David R Ebsworth director | $25k 1,904 shares | -0% | |
| 26Weak | Verona Pharma plc | Martin Edwards director | $142k 10,808 shares | -6% | |
| 26Weak | Verona Pharma plc | Andrew Fisher General Counsel | $126k 9,584 shares | -2% | |
| 27Weak | Verona Pharma plc | Mark W Hahn Chief Financial Officer | $2.7M 208,912 shares | -2% | |
| 17Weak | Verona Pharma plc | Kathleen A. Rickard Chief Medical Officer | $767k 58,336 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.